MicroRNA Regulation and Cancer Treatment (G3396)

Target Name: MRPL58

NCBI ID: G3396

MRPL58

MicroRNA Regulation and Cancer Treatment

MRPL58 (MutL homolog 58) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of microRNA (miRNA) expression in many organisms, including humans.

MicroRNAs are small non-coding RNAs that are involved in a variety of cellular processes, including gene regulation, cell signaling, and tissue development. They are produced by a process called miRNA processing, in which RNA viruses infect cells and use their enzymes to cut and modify the host RNA. This process can lead to the production of small, non-coding RNAs that can interact with target genes and regulate their activity.

MRPL58 is one of the key regulators of miRNA expression in E. coli, a bacterium that is commonly used in research studies. It is a member of the MutL family of proteins, which are involved in the regulation of gene expression in E. coli. MutL proteins function by binding to specific DNA sequences and preventing the binding of RNA polymerase, a protein that is involved in the production of RNA from DNA templates.

In addition to its role in regulating miRNA expression, MRPL58 is also a potential drug target. Many diseases, including cancer, are caused by the overproduction or underproduction of certain proteins or RNA molecules. By targeting MRPL58, researchers may be able to develop new treatments for a variety of diseases.

One of the ways that MRPL58 may be targeted as a drug is through its role in the regulation of cell signaling pathways. Many proteins that are involved in cell signaling pathways, such as tyrosine kinases and G-protein-coupled receptors, are regulated by miRNA. By inhibiting the activity of these proteins, MRPL58 may be able to block the formation of new biomolecules that could lead to the development of cancer.

Another potential mechanism by which MRPL58 may be targeted as a drug is through its role in the regulation of stem cell proliferation. Stem cells are a type of cell that have the ability to develop into any type of cell in the body. They are often used in research studies as a source of new cells for studies of cancer, regenerative biology, and other fields.

MRPL58 may be able to regulate the proliferation of stem cells by miRNA. For example, studies have shown that MRPL58 can inhibit the activity of the miR-18a, a miRNA that is involved in stem cell proliferation. This suggests that by targeting MRPL58, researchers may be able to develop new treatments for the proliferation of stem cells that could lead to the development of cancer.

In addition to its potential as a drug target, MRPL58 may also be a valuable biomarker for the diagnosis and treatment of cancer. miRNA expression is often altered in cancer cells, and researchers have used miRNA as a diagnostic tool to identify the presence of cancer.

Studies have shown that miRNA expression is often altered in a variety of cancer types, including breast, lung, and ovarian cancers. For example, studies have shown that miR-18a is often expressed in breast cancer cells, and that its levels are often decreased in breast cancer cells compared to healthy breast tissue.

Similarly, miR-18a has been shown to be expressed in lung cancer cells, and that its levels are often decreased in lung cancer cells compared to healthy lung tissue. In ovarian cancer, miR-18a has been shown to be expressed in the cells, and that its levels are often decreased in ovarian cancer cells compared to healthy ovarian tissue.

These findings suggest that miRNA expression may be a valuable biomarker for the diagnosis and treatment of cancer. By targeting MRPL58, researchers may be able to develop new treatments for a variety of cancer types.

In conclusion, MRPL58 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is involved in the regulation of miRNA expression in E. coli, and it may be able to

Protein Name: Mitochondrial Ribosomal Protein L58

Functions: Essential peptidyl-tRNA hydrolase component of the mitochondrial large ribosomal subunit. Acts as a codon-independent translation release factor that has lost all stop codon specificity and directs the termination of translation in mitochondrion, possibly in case of abortive elongation. May be involved in the hydrolysis of peptidyl-tRNAs that have been prematurely terminated and thus in the recycling of stalled mitochondrial ribosomes

The "MRPL58 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MRPL58 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets